3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
8
Recruiting
3
Unknown
2
Terminated
2
Active not recruiting
2
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
3
Conditions
Carcinoma, Non-Small-Cell Lung
37
Breast Neoplasms
26
Prostatic Neoplasms
22
Stomach Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
12
Lung Neoplasms
11
Neoplasms
10
Urinary Bladder Neoplasms
8
Head and Neck Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Squamous Cell
6
Non-Muscle Invasive Bladder Neoplasms
5
Nasopharyngeal Carcinoma
5
Carcinoma, Transitional Cell
5
Adenocarcinoma
5
Oropharyngeal Neoplasms
4
Sarcoma
3
Prostatic Neoplasms, Castration-Resistant
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Vaccinia
2
Recurrence
2
Peritoneal Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Melanoma
2
Interventions
pembrolizumab
25
Paclitaxel
20
Carboplatin
17
Bevacizumab
12
Specimen Handling
10
Letrozole
10
abemaciclib
7
dostarlimab
6
Taxes
6
Fulvestrant
6
Megestrol Acetate
5
Medroxyprogesterone Acetate
5
Magnetic Resonance Spectroscopy
5
Drug Therapy
5
Doxorubicin
5
Cisplatin
5
Blood Specimen Collection
5
Biopsy
5
olaparib
4
lenvatinib
4
atezolizumab
4
Radiotherapy
4
Progestins
4
Observation
4
Nivolumab
4
Immunoglobulin G
4
Gemcitabine
4
trastuzumab deruxtecan
3
palbociclib
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Endometrial Neoplasms
×
Docetaxel
×
Clear all
NCT06952504
2026-05-22
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,123 enrolled
NCT06340568
2026-05-20
Fern-EC-01
BioNTech SE
Phase 3
Recruiting
480 enrolled
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled